Skip to main content
. 2019 Nov 1;105(3):890–897. doi: 10.1210/clinem/dgz163

Figure 3.

Figure 3.

Proportion of participants achieving bone mineral density increases of >3%, >6%, and >9% at the total hip, femoral neck, and lumbar spine from baseline to 9 and 15 months.a BL, baseline; HD, high-dose teriparatide (40-μg) plus denosumab; M, month; SD, standard-dose teriparatide (20 μg) plus denosumab.

*P < .05.

**P < .01.

aIncludes 60 participants who had areal bone mineral density (aBMD) determinations at all study visits (baseline, month 9, and month 15, 79% of the Denosumab and High-Dose Teriparatide Administration population at enrollment). Data missing for 1 participant in the SD group for femoral neck aBMD at 9 and 15 months; and 2 participants in the SD group and 2 participants in the HD group for lumbar spine aBMD at 9 and 15 months.